| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPA-3 | GDSC1000 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.032 | 0.3 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | GW 441756 | GDSC1000 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | TPCA-1 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.3 |
| mRNA | VX-680 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.3 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.048 | 0.3 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.3 |